Director CMC Drug Substance: Small Molecules and Biologics
Glaukos
Director CMC Drug Substance: Small Molecules and Biologics
Glaukos
Medical devices for glaucoma treatment
How You’ll Contribute
Leading the strategy and operational implementation for R&D, pre-clinical and clinical product development and manufacturing (Contract Development and Manufacturing - CDMOs): life cycle management to ensure robust, compliant, and efficient production of active pharmaceuticals including small molecules, biologics and oligonucleotides across the company’s product portfolio. This role provides technical and operational leadership for API development and commercialization, ensuring consistent supply, regulatory compliance, quality performance, cost optimization, and alignment with overall business objectives.
This individual serves as the primary liaison between Research & Development, Manufacturing, Quality, Regulatory Affairs, Supply Chain, and external manufacturing partners to advance active pharmaceuticals development across salient programs from development through commercial production. This individual will serve as the subject matter expert for API manufacturing technologies, raw materials, and process optimization.
What You’ll Do
How You’ll Get There
Required Qualifications
#GKOS_US
Job Salary Range: 190,800.00 - 238,500.00
Glaukos focuses on ophthalmology by developing and commercializing medical devices and therapies for glaucoma, corneal disorders, and retinal diseases. Its products mainly target surgeons who treat eye conditions, with a core technology in micro invasive glaucoma surgery (MIGS). The company’s MIGS devices, such as the Trabecular Micro Bypass Stent and next-generation iStent, are implanted in the eye to improve outflow of eye fluid and lower intraocular pressure, offering a less invasive option compared with traditional surgeries. Glaukos differentiates itself by pioneering MIGS and bringing the first US-approved MIGS device to market in 2012, continuing to expand its portfolio through research, development, and strategic acquisitions. The company aims to improve patient care by providing safer, effective, and longer-lasting treatment options for glaucoma and related eye diseases, addressing unmet needs in ophthalmology.
Explore more opportunities at Glaukos